Preserflo microshunt implant for the treatment of refractory uveitic glaucoma: 36-month outcomes.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
06
05
2022
accepted:
12
12
2022
revised:
26
11
2022
pmc-release:
01
08
2024
medline:
4
8
2023
pubmed:
29
12
2022
entrez:
28
12
2022
Statut:
ppublish
Résumé
To determine 36-month efficacy and safety outcomes of the PRESERFLO Microshunt implant in the treatment of refractory uveitic glaucoma. Consecutive patients with uncontrolled uveitic glaucoma despite maximum medical treatment received PRESERFLO Microshunt implant with mitomycin C (MMC) in a tertiary referral glaucoma practice. Efficacy and safety outcomes data were collected at month 6, 12, 24, and 36, postoperatively. The primary outcome was surgical success, defined as intraocular pressure (IOP) between 5 and 21 mmHg or > 20% reduction from baseline, and absence of criteria for surgical failure. Secondary outcomes were IOP, visual acuity (VA), use of glaucoma medical therapy, surgical complications, rate of reoperation for glaucoma. 21 eyes of 21 patients were included. The mean rate of success was 0.74 (95%CI 0.48-0.88), 0.68 (0.43-0.84), 0.47 (0.25-0.67), and 0.47 (0.25-0.67, at 6, 12, 24, and 36 months postoperatively, respectively. The mean IOP decreased by 30.7% (95% CI 13.7-47.7), 26.5% (95% CI 3.2-49.8), 33.5% (95% CI 21.8-45.3), and 30.1% (95% CI 7.2-52.9) from baseline at postoperative month 6, 12, 24, and 36, respectively (p < 0.001). The mean ± SD number of glaucoma medications decreased from 4.1 ± 0.9 to 0.9 ± 1.2 at the final follow up (p = 0.0005). No sight-threatening complications were reported by 36 months. Three-year results of the PRESERFLO Microshunt implant demonstrated favourable efficacy and safety profile in the treatment of refractory uveitic glaucoma.
Identifiants
pubmed: 36577805
doi: 10.1038/s41433-022-02368-w
pii: 10.1038/s41433-022-02368-w
pmc: PMC10397285
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2535-2541Informations de copyright
© 2022. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.
Références
Clin Ophthalmol. 2015 Dec 07;9:2291-8
pubmed: 26672771
Clin Exp Ophthalmol. 2018 May;46(4):339-345
pubmed: 29053204
J Glaucoma. 2016 Sep;25(9):744-9
pubmed: 27552504
Arch Ophthalmol. 1988 Mar;106(3):392-5
pubmed: 3278704
Eye (Lond). 2009 Jul;23(7):1509-17
pubmed: 19521438
Ophthalmology. 2012 Apr;119(4):694-702
pubmed: 22196977
Am J Ophthalmol. 2005 Aug;140(2):275-87
pubmed: 16086949
Arch Ophthalmol. 2004 Jun;122(6):838-44
pubmed: 15197058
Curr Opin Ophthalmol. 1999 Apr;10(2):112-6
pubmed: 10537760
Ophthalmology. 2001 Mar;108(3):621-6
pubmed: 11237919
J Glaucoma. 2002 Jun;11(3):189-96
pubmed: 12140394
Am J Ophthalmol. 2020 Jul;215:141-153
pubmed: 32173344
Clin Exp Ophthalmol. 2017 May;45(4):393-400
pubmed: 27928879
Am J Ophthalmol. 2007 Jul;144(1):62-69
pubmed: 17493574
Br J Ophthalmol. 2020 Dec;104(12):1652-1657
pubmed: 32245851
J Ophthalmic Inflamm Infect. 2018 Jun 18;8(1):9
pubmed: 29915970
Ophthalmology. 2018 May;125(5):774-781
pubmed: 29248173
Ocul Immunol Inflamm. 2009 Jul-Aug;17(4):243-8
pubmed: 19657977
Eye (Lond). 1993;7 ( Pt 4):495-501
pubmed: 7902819
Ocul Immunol Inflamm. 2020 Jul 3;28(5):833-838
pubmed: 31418636
Curr Opin Ophthalmol. 2020 Mar;31(2):132-138
pubmed: 31922979
Eye (Lond). 2023 Mar;37(4):644-649
pubmed: 35277663
J Glaucoma. 2017 Aug;26(8):687-693
pubmed: 28692597
Ophthalmology. 2002 Dec;109(12):2256-60
pubmed: 12466167
Am J Ophthalmol. 2019 Nov;207:144-150
pubmed: 31251907
J Glaucoma. 2016 Feb;25(2):e58-65
pubmed: 26766400
Graefes Arch Clin Exp Ophthalmol. 2016 Dec;254(12):2439-2448
pubmed: 27495303
Prog Brain Res. 2015;221:243-69
pubmed: 26518082
Am J Ophthalmol. 2018 May;189:96-101
pubmed: 29499173